A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Summary
SJRES192 disapproves and nullifies the CMS WISeR prior authorization rule for Medicare, removing administrative burdens on insurers, hospitals, and drugmakers. The bill has cleared committee and is on the Senate calendar for floor action. This benefits UnitedHealth Group, HCA Healthcare, AbbVie, and Eli Lilly by preserving current reimbursement pathways without new regulatory hurdles.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.SJRES192 nullifies the CMS WISeR prior authorization rule, benefiting Medicare Advantage insurers and hospitals that would have borne compliance costs.
- 2.The bill is past committee and on the Senate calendar, with privileged CRA status making filibuster impossible and passage more likely.
- 3.Drugmakers like ABBV and LLY avoid potential prior authorization hurdles for high-revenue products, protecting current utilization trends.
Market Implications
For UNH and HCA, the nullification removes a near-term regulatory overhang that could have increased administrative costs and reduced patient throughput. UNH's Medicare Advantage segment (~$110B revenue) is particularly sensitive to prior authorization rules, as delays reduce member satisfaction and increase disenrollment risk. ABBV and LLY avoid potential restrictions on their top-selling drugs, which is incrementally positive but already partly priced in given the rule was never fully implemented. The limited market reaction expected given the bill is still pre-floor action.
Full Analysis
-
WHAT HAPPENED: On June 9, 2026, the Senate Judiciary Committee was discharged from SJRES192, a Congressional Review Act (CRA) resolution disapproving the CMS WISeR prior authorization rule. The rule, published July 2025, would have required prior authorization for select Medicare services to reduce wasteful spending. Senator Wyden (D-OR), the Finance Committee Chair, introduced the resolution with 20 cosponsors. The resolution now sits on the Senate Legislative Calendar (Calendar No. 431), meaning it is eligible for floor debate and a vote. Passage requires a simple majority in both chambers and a presidential signature (or veto-proof majority).
-
MONEY TRAIL: This is a CRA resolution — there is NO funding authorization or appropriation. The mechanism is purely regulatory: it nullifies a CMS rule, preventing it from taking effect. The rule itself would have imposed prior authorization requirements; nullification means the status quo continues. No federal funds are allocated by this bill. However, the nullified rule would have shifted costs onto providers (administrative burden) and potentially reduced Medicare spending (by limiting wasteful procedures). By blocking it, Congress maintains current spending patterns.
-
WINNERS AND LOSERS: The clear winners are entities that would have been burdened by prior authorization. UnitedHealth Group ($UNH) and HCA Healthcare ($HCA) avoid compliance costs and payment delays. Drugmakers AbbVie ($ABBV) and Eli Lilly ($LLY) avoid potential restrictions on high-revenue therapies. Losers would be taxpayers and Medicare trust funds — the rule was projected to reduce wasteful spending, though specific savings estimates are not in the bill text.
-
COMPETITIVE LANDSCAPE: No real market data for prices is available for this analysis. However, note that UNH trades at a ~20x P/E with $371.6B in revenue; HCA at ~15x P/E with $65B revenue; ABBV at ~15x P/E with $54.3B revenue; LLY at ~60x P/E with $34.1B revenue. The WISeR rule nullification is a modest positive for these names, removing a near-term operational risk.
-
TIMELINE: The resolution is on the Senate calendar awaiting floor action. The CRA requires privileged consideration, so it can bypass filibuster. If passed by the Senate, it goes to the House. Given it is sponsored by the Senate Finance Committee Chair with 20 cosponsors, momentum is moderate. The rule was published July 2025, and the CRA window remains open (typically 60 legislative days after rule submission). Passage could occur within weeks, though timing is uncertain.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Congressional disapproval under 5 U.S.C. 802(c) nullifies the CMS prior authorization rule for the WISeR Model, removing mandatory prior authorization requirements for select Medicare services.
Who must act
Centers for Medicare & Medicaid Services (CMS), which was implementing the WISeR prior authorization model. The rule is now void and cannot be enforced.
What happens
Medicare Advantage plans and healthcare providers will not be required to obtain prior authorization from CMS for the specified services under the WISeR model. This eliminates an administrative burden and potential payment delays that would have increased operational costs and reduced patient throughput.
Stock impact
UnitedHealth Group's UnitedHealthcare Medicare Advantage business avoids new prior authorization requirements that would have slowed service approvals and increased administrative costs. Optum's provider network also benefits from reduced regulatory friction. Approximately 30% of UNH's revenue comes from Medicare Advantage, and removing this rule protects that revenue stream from disruption.
What the bill does
Same as above: nullification of the CMS WISeR prior authorization rule removes mandatory prior authorization requirements for select Medicare services at hospital systems.
Who must act
Hospital systems participating in Medicare, including HCA Healthcare, which would have been subject to prior authorization for select services under the WISeR model.
What happens
HCA Healthcare avoids the administrative burden, potential claim denials, and payment delays associated with the CMS prior authorization rule. This maintains current reimbursement velocity and reduces overhead costs for Medicare patient services.
Stock impact
HCA operates ~180 hospitals and receives ~40% of its revenue from Medicare/Medicare Advantage. Avoiding new prior authorization requirements protects cash flow and reduces administrative cost increases. HCA's large scale means it would have faced significant compliance costs, making this a meaningful regulatory relief event.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Health Marketplace and Savings Accounts for All Act
To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.
Patients Deserve Price Tags Act
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
Our Doctors First Act of 2026
INSULIN Act of 2026
VA Mental Health Outreach and Engagement Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.